TTC17 and breast cancer: Moreover, among BC patients receiving paclitaxel-containing regimens as neoadjuvant or adjuvant chemotherapy, low TTC17 expression was positively associated with improved five-year RFS or preoperative pCR, further indicating the influence of TTC17 deficiency on the efficacy of paclitaxel.